We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In response to a request for information from the White House, PhRMA has offered recommendations for improving clinical trial infrastructure to enable effective responses to public health emergencies, including advice on trial diversity and participation in general. Read More
Insurers need more evidence of long-term safety and efficacy to make the best decisions about whether — and how — to cover Eisai’s Leqembi (lecanemab) for early Alzheimer’s disease, according to experts who participated in a policy discussion with the Institute for Clinical and Evidence Review (ICER). Read More
If approved, the candidate could provide the broadest meningococcal serogroup coverage thus far, and could lead to a simplified immunization schedule. Read More
Eli Lilly’s antiamyloid antibody solanezumab struck out in a highly anticipated phase 3 preclinical treatment study, failing to alter disease progression in people who had amyloid brain plaques but normal cognition.